TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10656170

Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg bid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg qd)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 30

Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 30
Study: 8683863

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy, daily subcutaneous doses of 2.5, 5.0 or 7.5 micrograms/kg for 7 or 14 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy with co-administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (Epo)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy with sequential administration of G-CSF and Epo two weeks after IL-3
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy
Number of subjects: 4
Study: 1861931

Group type: EXPERIMENTAL
Intervention: Albuterol syrup (2 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Metaproterenol syrup (10 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 65
Study: 6409599

Group type: EXPERIMENTAL
Intervention: Cinromide (1,200 to 4,800 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 4013351

Group type: EXPERIMENTAL
Intervention: 50 mg spironolactone + 20 mg furosemide (SF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 50 mg spironolactone + 5 mg butizide (SB)
Number of subjects: 22
Study: 29104022

Group type: EXPERIMENTAL
Intervention: Active learning intervention (physical activity combined with academic content)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Control group (sedentary classroom)
Number of subjects: 1129
Study: 27123570

Group type: EXPERIMENTAL
Intervention: BCG vaccination 0.05 ml intradermally in the upper left arm within seven days of birth
Number of subjects: 4262

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4262
Study: 24725468

Group type: EXPERIMENTAL
Intervention: Fixed value contingency management (three £10 vouchers)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Escalating value contingency management (£5, £10, and £15 vouchers)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Treatment as usual (no incentive)
Number of subjects: 210
Study: 22733474

Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus spironolactone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chlorthalidone alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus irbesartan
Number of subjects: 17
Study: 19949016

Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise program (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (n = 28)
Number of subjects: 57
Study: 18523846

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (A1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (A2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (B1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (B2)
Number of subjects: 64
Study: 15867200

Group type: EXPERIMENTAL
Intervention: FU/LV/bevacizumab (5 mg/kg once every 2 weeks)
Number of subjects: 490

Group type: COMPARATOR
Intervention: FU/LV or IFL (control group)
Number of subjects: 490
Study: 12705648

Group type: EXPERIMENTAL
Intervention: Leucofiltration of arterial blood throughout cardiopulmonary bypass (CPB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leucofiltration of a part of the venous return blood in the rewarming phase during CPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leucofiltration of residual heart‐lung machine blood during transfusion into the patient after CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without leucofiltration
Number of subjects: 40
Study: 10685270

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal-synchronized intermittent mandatory ventilation (NP-SIMV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nasopharyngeal continuous positive airway pressure (NPCPAP)
Number of subjects: 41
Study: 8932042

Group type: EXPERIMENTAL
Intervention: Standardized curriculum (experimental group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine-care control group
Number of subjects: 150
Study: 1756919

Group type: EXPERIMENTAL
Intervention: Endoscopic microwave coagulation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Endoscopic sclerosis
Number of subjects: 127
Study: 6643056

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil treatment following curettage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30451307

Group type: EXPERIMENTAL
Intervention: Abatacept treatment for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline CD4/CD8 ratio
Number of subjects: 12
Study: 29546527

Group type: EXPERIMENTAL
Intervention: 6 hours bed rest after intrathecal chemotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 8 hours bed rest after intrathecal chemotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 10 hours bed rest after intrathecal chemotherapy
Number of subjects: 390
Study: 25981194

Group type: EXPERIMENTAL
Intervention: Online gross anatomy examinations
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional 'steeplechase' examinations
Number of subjects: 45
Study: 24121245

Group type: EXPERIMENTAL
Intervention: Real-time feedback (RTF) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 22
Study: 22387716

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 20542806

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 208

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 208
Study: 17667198

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilatory assistance (NIV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous breathing test (SBT)
Number of subjects: 8
Study: 15652898

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 82
Study: 11838000

Group type: EXPERIMENTAL
Intervention: 1.5 g/d n-3 fatty acids
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 9543078

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg/daily)
Number of subjects: 20
Study: 7922063

Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study: 3289830

Group type: EXPERIMENTAL
Intervention: naproxen CR 1000 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: isoxicam 200 mg
Number of subjects: 100
Study: 4568356

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium 300 mg daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30101320

Group type: EXPERIMENTAL
Intervention: PT-F (Parent Training for Feeding problems)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 42
Study: 27928704

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1000 mg/day co-administered with piperine 10 mg/day)
Number of subjects: 118
Study: 25646817

Group type: EXPERIMENTAL
Intervention: Vaccine regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25129247

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol (DT) 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 0
Study: 23251152

Group type: EXPERIMENTAL
Intervention: Low glycemic index carbohydrates (Group 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: All types of carbohydrates (Group 1)
Number of subjects: 107
Study: 19304392

Group type: EXPERIMENTAL
Intervention: Pre-surgical pain severity
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pain-related fears of movement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interventions targeting pain-related psychological risk factors
Number of subjects: 75
Study: 17378918

Group type: EXPERIMENTAL
Intervention: Memantine (maximum dose of 40 mg/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 44
Study: 14749544

Group type: COMPARATOR
Intervention: Reference formulation (20 mg PO of prednisone)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test formulation (20 mg PO of prednisone)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simulated data sets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment of prednisone formulations
Number of subjects: 24
Study: 11413083

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) - 4-hour intravenous infusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 66
Study: 9068327

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 20
Study: 8111502

Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet for 6 weeks
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet for 18 weeks
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet
Number of subjects: 383
Study: 3518528

Group type: EXPERIMENTAL
Intervention: Enprofylline (1.0 mg/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Theophylline (3.0 mg/kg)
Number of subjects: 39
Study: 31952923

Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine (2·5×10^4 PFU, 2×10^5 PFU, 1·8×10^6 PFU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine (high-dose cohort)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29951651

Group type: EXPERIMENTAL
Intervention: NC containing red yeast rice, policosanols, resveratrol and chromium picolinate (10 mg of monacolin K)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet alone (Control)
Number of subjects: 30
Study: 28390210

Group type: EXPERIMENTAL
Intervention: 2% alumina toothpaste
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 1% alumina toothpaste
Number of subjects: 169

Group type: COMPARATOR
Intervention: Reference toothpaste (silica-based)
Number of subjects: 169
Study: 24831577

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (40 mg before treatment plus maintenance for 7 days)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (placebo before treatment plus 10 mg maintenance for 7 days)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Low-dose rosuvastatin
Number of subjects: 185
Study: 21911336

Group type: EXPERIMENTAL
Intervention: Individualized physical activity counseling (face-to-face meeting followed by telephone contacts every 4 months for 2 years)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Individualized physical activity counseling
Number of subjects: 632
Study: 20211830

Group type: EXPERIMENTAL
Intervention: Day shift
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Middle bay
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Quadrants at the back of a bay
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All sound levels
Number of subjects: 480
Study: 18027030

Group type: EXPERIMENTAL
Intervention: Knot-tying training on a VR simulator (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 20
Study: 16118813

Group type: EXPERIMENTAL
Intervention: Adherence to prescribed antiretroviral therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Long periods of time without intake adherence measures
Number of subjects: 35
Study: 12834992

Group type: EXPERIMENTAL
Intervention: Peer-drinking exposures
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Religious service attendance
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 444
Study: 10395118

Group type: EXPERIMENTAL
Intervention: Limited Sampling Model (LSM) for Drug A
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Limited Sampling Model (LSM) for Drug B
Number of subjects: 15
Study: 8879370

Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN (arm B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: 5-FU alone (arm A)
Number of subjects: 105
Study: 8284116

Group type: EXPERIMENTAL
Intervention: PRP‐OMP
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 35
Study: 3737785

Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 28804809

Group type: EXPERIMENTAL
Intervention: Therapeutic Patient Education (TPE) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPE program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific assessment criterion (subscale 9 of the Brief Pain Inventory)
Number of subjects: 0
Study: 26785220

Group type: EXPERIMENTAL
Intervention: 100 mg GSK2586184 twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg GSK2586184 twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg GSK2586184 twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24697586

Group type: EXPERIMENTAL
Intervention: Broadband ultraviolet A (BB-UVA) at 10 or 15 J/cm² per session
Number of subjects: 61

Group type: COMPARATOR
Intervention: Psoralen + UVA (PUVA)
Number of subjects: 61
Study: 22632852

Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 19752609

Group type: EXPERIMENTAL
Intervention: 12 core biopsy
Number of subjects: 244

Group type: COMPARATOR
Intervention: 15 core biopsy
Number of subjects: 244
Study: 17323185

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Risedronate (2.5 mg/day)
Number of subjects: 121
Study: 15062882

Group type: EXPERIMENTAL
Intervention: Cigar smoking
Number of subjects: 12
Study: 11133320

Group type: EXPERIMENTAL
Intervention: SPM spatial normalization method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAR (spatial transformation algorithm for registration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atlas-based adaptive smoothing method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaussian filtering method
Number of subjects: 0
Study: 10168532

Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride (10(-3)M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride (10(-2)M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7959995

Group type: EXPERIMENTAL
Intervention: Diuretic therapy (Group III)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No diuretic therapy (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (Group I)
Number of subjects: 0
Study: 2884723

Group type: EXPERIMENTAL
Intervention: Salazosulfapyridine (SI) at a dose of 2 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Salazosulfapyridine (SI)
Number of subjects: 60
Study: 28198205

Group type: EXPERIMENTAL
Intervention: 13 mg / day total MCs
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 27 mg / day total MCs
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 26268815

Group type: EXPERIMENTAL
Intervention: secukinumab 10 mg/kg i.v. every 2 weeks until week 10
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 24752228

Group type: EXPERIMENTAL
Intervention: Hypertrophic resistance exercise (HRE) - 1 repetition maximum (1 RM) control contractions and three sets of 13 RM (SET1-3)
Number of subjects: 11
Study: 24312382

Group type: EXPERIMENTAL
Intervention: Non-caloric sweetened (NS) drink
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sugar sweetened (SS) drink
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yoghurt drink
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 40
Study: 19808841

Group type: EXPERIMENTAL
Intervention: Strength-based skills training program for dementia caregiving dyads; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control group not available.
Number of subjects: 0
Study: 18438203

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Medical therapy (MT)
Number of subjects: 1200
Study: 16628063

Group type: EXPERIMENTAL
Intervention: Halothane (HAL) at 1.0 MAC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) at 1.0 MAC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV) at 1.0 MAC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Halothane (HAL) at 0.5 MAC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) at 0.5 MAC
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV) at 0.5 MAC
Number of subjects: 35
Study: 12913198

Group type: COMPARATOR
Intervention: SIVD
Number of subjects: 13
Study: 11044542

Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Alendronate Therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (untreated women)
Number of subjects: 57
Study: 8863905

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1889980

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or other antimigraine drugs
Number of subjects: 0
Study: 6647211

Group type: EXPERIMENTAL
Intervention: High dose salbutamol given by domestic nebulizers
Number of subjects: 0
Study: 31023422

Group type: EXPERIMENTAL
Intervention: 4-month (50 h) educational intervention to instill healthy behaviors related to diet, physical activity, body/heart awareness, and emotion management.
Number of subjects: 562

Group type: COMPARATOR
Intervention: Standard curriculum (control)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: 4-month (50 h) educational intervention
Number of subjects: 562
Study: 29912906

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 0
Study: 27506633

Group type: EXPERIMENTAL
Intervention: Marine complex supplement (Viviscal® Man); administered twice daily for 180 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; administered twice daily for 180 days
Number of subjects: 0
Study: 23824236

Group type: EXPERIMENTAL
Intervention: Universal screening for depression and subsequent care support
Number of subjects: 900
Study: 22030715

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 20467310

Group type: EXPERIMENTAL
Intervention: Iyengar yoga (IY)
Number of subjects: 24
Study: 17394695

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 493

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Undiagnosed patients (first 3 months follow-up)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Undiagnosed patients (after 3 years)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Known patients (after 3 years)
Number of subjects: 493
Study: 15802371

Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry (AR)
Number of subjects: 10
Study: 12217456

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments (Fluoxetine and CBT)
Number of subjects: 0
Study: 10543268

Group type: EXPERIMENTAL
Intervention: High PS (increased by at least 5 cmH2O)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low PS (decreased by at least 5 cmH2O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline PS
Number of subjects: 8
Study: 8847943

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2159838

Group type: EXPERIMENTAL
Intervention: PCV chemotherapy (cisplatin 100 mg/m2, cyclophosphamide 600 mg/m2, vindesine 3 mg/m2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 26
Study: 453063

Group type: EXPERIMENTAL
Intervention: High-fiber diet (18.0 g crude fiber)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-fiber diet (1.0 g crude fiber)
Number of subjects: 7
Study: 30277014

Group type: EXPERIMENTAL
Intervention: Needleless transcutaneous neuromodulation (TN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-TN
Number of subjects: 60
Study: 27578535

Group type: EXPERIMENTAL
Intervention: Medium-frequency medium duration (40 Hz × 360 s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 80
Study: 25795954

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (20 Hz and 2 mm, twice a week for 8 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 37